ArticleTranslational gastroenterology and hepatology2025
Development and validation of a basement membrane-associated immune prognostic model for hepatocellular carcinoma.
Article in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating the causal effects of circulating plasma proteins on the risk of malignant neoplasms of bone and articular cartilage.The Journal of international medical research · 2026Article
- Identification of basement membrane-based prognostic signature and potential therapeutic drugs in hepatocellular carcinoma.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC), one of the most common malignant tumors worldwide, has a poor prognosis primarily due to its invasive and metastatic characteristics. Cancer invasion through basement membrane (BM) is the pivotal initial step in tumor dissemination and metastasis. This study aimed to identify gene signatures associated with the BM to enhance the overall prognosis of HCC. Methods: In this study, we performed multiple bioinformatics analyses based on the RNA sequencing (RNA-seq) data and clinical information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. An unsupervised consistent cluster analysis was conducted on 370 HCC patients, categorizing them into two distinct groups based on the expression profiles of 222 BM-related genes. Differentially expressed genes (DEGs) between these clusters were identified, followed by functional enrichment analysis. To explore the differences between the groups, the Estimation of STromal and Immune cells in MAlignant Tumours using Expression data (ESTIMATE) and Cell type Identification By Estimating Relative Subsets Of known RNA Transcripts (CIBERSORT) algorithms were applied, along with the analysis of immune checkpoint molecules and human leukocyte antigen (HLA) expression levels. This helped in understanding the relationship between the HCC immune microenvironment and BM-related genes. A prognostic model was constructed using univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses, with its performance subsequently estimated and validated. Additionally, hub biomarkers genes were identified using machine learning techniques, followed by an analysis of their functions and relationships with clinical characteristics. Finally, single-cell clustering analysis was employed to further investigate the expression distribution of these genes within the HCC immune microenvironment. Results: Following consistent cluster analysis, two groups were identified: the BM high group and the BM low group. Among the 6,221 DEGs between the two groups, 5,863 were upregulated and 358 were downregulated, with enrichment functions primarily associated with extracellular matrix (ECM) organization, cell adhesion, immune response, and metabolism. The expression levels of BM-related genes were found to regulate the HCC immune microenvironment. Using univariate Cox regression analysis, 60 prognostic BM-related genes were identified, leading to the establishment of an 11-gene prognostic model named BMscore to predict the overall survival (OS) of HCC patients. The high BMscore group indicated worse prognosis, and the model's predictive performance was validated using the GEO dataset. Conclusions: A prognostic model based on BM-related genes was successfully developed and shows promise for evaluating prognoses and offering personalized treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.